datetime,headline,summary,related,lang,source
2020-11-20 02:54:43-05:00,Biohaven Pharmaceutical (NYSE:BHVN) Price Target Raised to $110.00,"Biohaven Pharmaceutical (NYSE:BHVN) had its price target boosted by Canaccord Genuity from $80.00 to $110.00 in a research report report published on Monday, The Fly reports. They currently have a buy rating on the stock. A number of other research analysts also recently weighed in on the stock. Wedbush upped their price objective on shares […]",BHVN,en,Transcript Daily
2020-11-09 03:32:00-05:00,Recap: Biohaven Pharmaceutical Q3 Earnings,Shares of Biohaven Pharmaceutical (NYSE:BHVN) traded flat in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per …,BHVN,en,Benzinga
2020-10-22 21:18:45-05:00,"Gregory Bailey Sells 3,748 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock","Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 3,748 shares of Biohaven Pharmaceutical stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $78.88, for a total transaction of $295,642.24. Following the sale, the director now owns 2,585,181 shares in the company, valued at $203,919,077.28. The […]",BHVN,en,Daily Political
2020-10-21 17:42:45-05:00,"Gregory Bailey Sells 4,554 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock","Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Gregory Bailey sold 4,554 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $78.98, for a total value of $359,674.92. Following the completion of the sale, the director now directly owns 2,585,181 shares in […]",BHVN,en,US Banking News
2020-08-10 08:44:07-05:00,Biohaven Pharmaceutical : 2Q Earnings 2020 | MarketScreener,"2nd Quarter 2020 Earnings August 10, 2020 Ellie, living with migraine … | August 10, 2020",BHVN,en,MarketScreener
2020-08-05 16:00:00-05:00,"Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020","NEW HAVEN, Conn., Aug. 5, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, will hold its upcoming…",BHVN,en,PR Newswire
2020-07-16 04:45:38-05:00,Biohaven Pharmaceutical's Migraine Drug To Be Promoted by Khloe Kardashian,"Biohaven Pharmaceutical Holding Co. Ltd.'s (NYSE: BHVN ) ""Nurtec ODT"" drug will be promoted by media personality Khloe Kardashian, the company announced Wednesday. What Happened Kardashian is joining the New Haven, Connecticut-based company's ""Take Back Today"" campaign, aimed at promoting the recently-launched orally dissolving tablet for people suffering from migraines. The 36-year old, of the ""Keeping Up with the Kardashians"" fame, said in a statement that she has been taking the … Full story available on Benzinga.com",BHVN,en,Benzinga
2020-05-04 07:47:00-05:00,Why Biohaven (BHVN) Might Surprise This Earnings Season,Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,BHVN,en,Zacks Investment Research
2020-04-27 06:30:00-05:00,Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC™ ODT in the Middle East,"NEW HAVEN, Conn., April 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (""Biohaven"") and Genpharm Services, a leading partner for innovative pharmaceuticals in Dubai, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in the Middle East…",BHVN,en,PR Newswire
2020-04-16 16:42:00-05:00,Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19,"NEW HAVEN, Conn., April 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that its Board of Directors has decided to hold the company's 2020 Annual Meeting of Shareholders on Thursday, April 30, 2020 at 10:00 a.m. Atlantic Time (9:00 a.m….",BHVN,en,PR Newswire
2020-04-16 06:30:00-05:00,Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC™ ODT In Israel,"NEW HAVEN, Conn., April 16, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) (""Biohaven"") and Medison Pharma, Israel's leading partner for innovative pharmaceuticals, announced today an agreement to distribute NURTEC™ ODT (rimegepant) in Israel. NURTEC ODT is…",BHVN,en,PR Newswire
2020-04-07 06:30:00-05:00,"Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC™ ODT","/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced a collaboration with Cove, a company providing specialized care and…",BHVN,en,PR Newswire
2020-03-13 06:30:00-05:00,Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC™ ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults,"NEW HAVEN, Conn. , March 13, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) today announced a Patient Savings Program for NURTEC™ ODT (rimegepant) that is now available for eligible commercially insured patients. The co-pay savings card can be obtained at the www.nurtec.com website after 12pm today. The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020 . NURTEC ODT, which disperses almost instantly in a person's mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine. BJ Jones, Chief Commercial Officer of Migraine and Common Diseases commented, ""We are committed to helping ensure people with migraine have access to the treatments they need and therefore have established a comprehensive, best-in-class suite of patient affordability and access programs, including a patient starter kit and a co-pay savings card which will allow patients with commercial insurance to pay as little as $0 for Nurtec ODT."" Mr.",BHVN,en,Benzinga Feeds
2020-03-12 15:30:00-05:00,Biohaven's NURTEC™ ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults,"NEW HAVEN, Conn. , March 12, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company (NYSE: BHVN ) today announced that NURTEC™ ODT (rimegepant) is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020 . NURTEC ODT, which disperses almost instantly in a person's mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine. BJ Jones, Chief Commercial Officer for Migraine and Common Diseases at Biohaven stated, ""At Biohaven, helping those with migraine is personal to us. We understand the widespread and debilitating effects that patients experience. The urgency to provide new treatment options for the millions who live with it each day has underscored our efforts to bring NURTEC ODT to pharmacies quickly."" Mr. Jones added, ""Biohaven is dedicated to minimizing barriers to medication access for people with migraine and has developed a suite of programs to help patients and physicians process access NURTEC ODT."" Treatment with NURTEC ODT is simple – a single dose of 75 mg provides fast pain relief, returns patients to normal function within one hour, and delivers sustained efficacy that lasts up to 48 hours for many patients, allowing people with migraine to get back to living their lives.",BHVN,en,Benzinga Feeds
2020-02-27 16:11:00-05:00,Biohaven's NURTEC™ ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults,"NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first…",BHVN,en,PR Newswire
2020-01-31 17:00:00-05:00,Biohaven Appoints Michael Heffernan To Board Of Directors,"NEW HAVEN, Conn., Jan. 31, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Michael Heffernan to its Board of Directors (""Board""). Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial…",BHVN,en,PR Newswire
2020-01-30 09:02:00-05:00,Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock,Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.,BHVN,en,Zacks Investment Research
2020-01-29 07:34:00-05:00,Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares,"NEW HAVEN, Conn., Jan. 29, 2020 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced…",BHVN,en,PR Newswire
2020-01-13 11:29:00-05:00,Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments,"NEW HAVEN, Conn., Aug. 8, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the ""Company""), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today…",BHVN,en,PR Newswire
2019-12-06 07:30:00-05:00,Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study,"NEW HAVEN, Conn., Dec. 6, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced…",BHVN,en,PR Newswire
2019-11-05 07:30:00-05:00,Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole,"NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it…",BHVN,en,PR Newswire
2019-11-04 17:00:46-05:00,"Biohaven Pharmaceutical : Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board | MarketScreener","11/04/2019 Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board - Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing… | November 4, 2019",BHVN,en,MarketScreener
2019-10-28 06:30:00-05:00,Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole,"NEW HAVEN, Conn., Oct. 28, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologic and neuropsychiatric diseases, today announced that it…",BHVN,en,PR Newswire
2019-06-11 10:53:00-05:00,Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock,Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.,BHVN,en,Zacks Investment Research
2019-05-20 11:53:25-05:00,3 Gene Therapy Stocks For A Biotech Portfolio,No summary available.,BHVN,en,Seeking Alpha
2019-05-17 07:03:47-05:00,"The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering","Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced lifting of FDA's partial clinical hold on the second cohort of Phase 1 study of its wet age-related macular degeneration drug) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Fate Therapeutics Inc (NASDAQ: FATE ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Masimo Corporation (NASDAQ: MASI )(received FDA nod for Radius PPG, a tetherless sensor solution) MediciNova, Inc. (NASDAQ: MNOV ) MeiraGTx Holdings PLC (NASDAQ: MGTX ) TransMedics Group Inc (NASDAQ: TMDX ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 16) Auris Medical Holding Ltd (NASDAQ: EARS ) CELLECT BIOTECH/S ADR (NASDAQ: APOP )(announced exploration of strategic alternatives) Enochian Biosciences Inc (NASDAQ: ENOB ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nuvectra Corp (NASDAQ: NVTR )(announced departure of COO and CFO) Precision Therapeutics Inc (NASDAQ: AIPT )(reacted to its first-quarter results) Sellas Life Sciences Group Inc (NASDAQ: SLS ) (reacted to its first-quarter results) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tonix …",BHVN,en,Benzinga
2019-05-10 16:04:05-05:00,Biohaven Pharmaceutical (BHVN) Presents At American Academy of Neurology Annual Meeting - Slideshow,No summary available.,BHVN,en,Seeking Alpha
2019-05-08 07:24:39-05:00,Biohaven's migraine med rimegepant shows positive effect when dosed on schedule,No summary available.,BHVN,en,Seeking Alpha
2019-05-07 06:22:25-05:00,Biohaven Pharmaceuticals beats by $0.09,No summary available.,BHVN,en,Seeking Alpha
2019-05-05 07:00:21-05:00,Uber Time (Stocks To Watch Podcast),No summary available.,"BHVN,BIIB,BKNG",en,Seeking Alpha
2019-04-29 12:22:32-05:00,"Market At New Highs, But Healthcare And Biotechs Feel The Heat",No summary available.,"BHVN,BIIB",de,Seeking Alpha
2019-04-23 06:00:00-05:00,"(BHVN) - SVB Leerink Maintains Outperform on Biohaven Pharmaceutical Holding Company Ltd. Common Shares, Raises Price Target to $67","This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …",BHVN,en,Benzinga
2019-04-16 07:10:46-05:00,"The Daily Biotech Pulse: J&J Earnings, FDA Nod For Mediconova, Proteon To Explore Strategic Alternatives","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN )(the company is said to explore a potential sale ) Medtronic PLC (NYSE: MDT ) Vermillion, Inc. (NASDAQ: VRML ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 15) Achaogen Inc (NASDAQ: AKAO )(announced bankruptcy filing) Acorda Therapeutics Inc (NASDAQ: ACOR ) Aethlon Medical, Inc. (NASDAQ: AEMD ) Assembly Biosciences Inc (NASDAQ: ASMB )(presented interim mid-stage results of its hepatitis B virus treatment candidate ABI-H0731) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Conatus Pharmaceuticals Inc (NASDAQ: CNAT )(announced Phase 2 clinical trial evaluating emricasan in NASH patients with cirrhosis and severe portal hypertension) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Imv Inc (NASDAQ: IMV ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) Vaxart Inc (NASDAQ: VXRT ) Verastem Inc (NASDAQ: VSTM ) See Also: The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs Stock In Focus Motif Says New Iclaprim Data Shows Comparable Efficacy With Standard-of-care MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) presented additional data for iclaprim at the 28th European Congress of Clinical Microbiology and Infectious Diseases, which showed it had comparable efficacy to vancomycin in treating acute bacterial skin and skin structure infection, or ABSSSI, lesions.",BHVN,en,Benzinga
2019-04-12 19:05:53-05:00,Here's Why Biohaven Pharmaceutical Jumped 20% Today,What happened Shares of Biohaven Pharmaceutical NYSE BHVN closed up 20 on Friday after Bloomberg reported that the drugmaker is exploring options including the potential sale of the company Unnamed sources claim that Biohaven has attracted interest from potential bidders,BHVN,en,Nasdaq
2019-03-22 07:16:07-05:00,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 21) Abbott Laboratories (NYSE: ABT ) Baxter International Inc (NYSE: BAX ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) CareDx Inc (NASDAQ: CDNA ) Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ) CYCLERION THERA/SH (NASDAQ: CYCNV ) Glaukos Corp (NYSE: GKOS ) Masimo Corporation (NASDAQ: MASI ) Merck & Co., Inc. (NYSE: MRK ) Qiagen NV (NYSE: QGEN ) Uniqure NV (NASDAQ: QURE ) Veracyte Inc (NASDAQ: VCYT ) XBiotech Inc (NASDAQ: XBIT ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on March 21) Biogen Inc (NASDAQ: BIIB )( discontinued development of one of its Alzheimer's candidate aducanumab) Unity Biotechnology Inc (NASDAQ: UBX ) Stock In Focus Immutep Granted U.S. Patent For its Cancer Treatment Method Australian biotech IMMUTEP LTD/S ADR (NASDAQ: IMMP ) has been granted a new patent entitled … Full story available on Benzinga.","BHVN,BIIB",en,Benzinga
2019-03-21 14:58:16-05:00,Sell-siders say Biogen may seek acquisitions after aducanumab fail,No summary available.,"BHVN,BIIB",en,Seeking Alpha
2019-03-18 07:38:11-05:00,Biohaven to raise $200M to fund priority review voucher buy,No summary available.,BHVN,en,Seeking Alpha
2019-03-14 06:47:21-05:00,Late-stage study of Biohaven's troriluzole in rare neurodegenerative disorder underway,No summary available.,BHVN,en,Seeking Alpha
2019-03-13 07:33:24-05:00,Biohaven nearing the finish line with migraine med Zydis,No summary available.,BHVN,en,Seeking Alpha
2019-02-28 16:49:41-05:00,Biohaven Pharmaceuticals reports Q4 results,No summary available.,BHVN,en,Seeking Alpha
2019-02-20 08:39:31-05:00,Biohaven enrolls first patient in Phase 3 GAD trial of troriluzole,No summary available.,BHVN,en,Seeking Alpha
